🎉 M&A multiples are live!
Check it out!

Public Comps and Valuation Multiples
for Regenerative Medicine

Benchmark revenue and EBITDA valuation multiples for public comps like Kolon TissueGene, CRISPR Therapeutics, Mesoblast, VCANBIO and Vericel.

Regenerative Medicine

See analyst estimates and all valuation multiples for Regenerative Medicine
Company EV EV/Revenue EV/EBITDA
$121B 10.7x 54.4x
$10.8B 3.7x 15.8x
$4.3B 12.6x 34.5x
$2.5B 743.5x -87.1x
$2.3B 8.9x 21.9x
$2.3B 4.1x 38.5x
$2.0B 8.1x 34.5x
$1.6B 36.3x -3.6x
$1.4B 90.6x -30.0x
$1.2B 5.0x 29.5x
$1.1B 496.2x -50.2x
$1.0B 15.9x -2.4x
$899M 2.5x 11.6x
$726M 3.7x 32.0x
$565M 1.2x 11.7x
$402M 13.0x -2.4x
$397M n/a n/a
$390M 6.7x 33.0x
$382M 12.7x 26.1x
$364M 9.8x -13.1x
$357M 6.5x -0.7x
$328M 24.7x -1.4x
$302M n/a n/a
$232M 91.3x n/a
$207M 0.6x n/a
$178M 36.9x -51.7x
$170M 6.4x 13.3x
$169M 1.4x 12.4x
$164M n/a n/a
$106M 3.9x -8.2x
$106M n/a n/a
$92.0M n/a n/a
$79.4M 1.6x 48.8x
$69.6M n/a -5.2x
$50.7M 30.3x n/a
$48.3M 4.8x -2.2x
$41.5M n/a n/a
$36.2M n/a n/a
$27.6M n/a n/a
$21.1M 27.6x n/a
$21.1M n/a n/a
$18.9M 4.9x n/a
$8.2M 1.4x n/a
$4.1M 1.7x n/a
-$250M -4.3x 1.2x
-$253M -4757.5x 1.4x

Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.

See analyst estimates and M&A multiples for Regenerative Medicine

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.